Cargando…

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

BACKGROUND: Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-apoptosis, anti-amyloid-β oligomers, and anti-hyperphosphorylated tau. OBJECTIVES: To investigate bryostatin safety, tolerability, and efficacy to improve cognition in advanced Alzheimer’s disease (AD) patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Farlow, Martin R., Thompson, Richard E., Wei, Lee-Jen, Tuchman, Alan J., Grenier, Elaine, Crockford, David, Wilke, Susanne, Benison, Jeffrey, Alkon, Daniel L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398557/ https://www.ncbi.nlm.nih.gov/pubmed/30530975 http://dx.doi.org/10.3233/JAD-180759

Ejemplares similares

Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease in the Absence of Memantine(1)
por: Thompson, Richard E., et al.
Publicado: (2022)

Advanced Alzheimer’s Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial
por: Alkon, Daniel L., et al.
Publicado: (2023)

Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
por: Cogram, Patricia, et al.
Publicado: (2020)

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials
por: Nelson, Thomas J., et al.
Publicado: (2017)

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
por: Nakamura, Yu, et al.
Publicado: (2014)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.
por: Thompson, C. H., et al.
Publicado: (1996)

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
por: Lopes, Maria Isabel, et al.
Publicado: (2021)

Randomised, Placebo-Controlled, Double-Blind Study of Oral Tranexamic Acid in the Treatment of Moderate-to-Severe Melasma in an Australian Cohort
por: Bala, Harini Rajgopal, et al.
Publicado: (2022)

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
por: Tyring, Stephen K., et al.
Publicado: (2023)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial
por: Hagen, Neil A., et al.
Publicado: (2017)

Randomized, placebo controlled, double blinded pilot superiority phase 2 trial to evaluate the effect of curcumin in moderate to severe asthmatics
por: Quan, Michele, et al.
Publicado: (2021)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021)

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study
por: Zhao, Y., et al.
Publicado: (2021)

Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial
por: Kumar, Vijay, et al.
Publicado: (2022)

Clinical evaluation of patients with moderate to severe Alzheimer disease
por: Varandas, Paulo Rogério Borges Rosmaninho, et al.
Publicado: (2007)

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
por: Koh, Seong-Ho, et al.
Publicado: (2021)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships
por: Kedei, Noemi, et al.
Publicado: (2015)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

Reliability and validity of the severe impairment battery in Taiwanese patients with moderate to severe Alzheimer’s disease
por: Huang, Mao-Hsuan, et al.
Publicado: (2020)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
por: Hanania, Nicola A, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
por: Suckfüll, Markus, et al.
Publicado: (2011)

The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2020)

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
por: Glatt, Sophie, et al.
Publicado: (2021)

Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial
por: Shokrani, Marjan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n254mn2vsm94nt4pa8mmofditp